The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)

• Published in: Critical reviews in oncology/hematology Vol. 89; no. 1; pp. 112 - 128
• Main Authors: Lambertini, Matteo, Del Mastro, Lucia, Bellodi, Andrea, Pronzato, Paolo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ireland Ltd 01.01.2014
• Subjects: Animals; Bone and Bones - drug effects; Bone pain; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - adverse effects; Granulocyte Colony-Stimulating Factor - therapeutic use; Granulocyte-colony stimulating factors; Hematology, Oncology and Palliative Medicine; Humans; Incidence; Pain - chemically induced; Pain - epidemiology; Pain - etiology; Pain Management; Granulocyte-colony stimulating factors; Bone pain

Abstract Granulocyte-colony stimulating factors (G-CSFs) are commonly employed in clinical practice. The most relevant adverse event of G-CSF administration is bone pain. Approximately 20% of cancer patients experienced bone pain with the administration of prophylactic daily G-CSFs (lenograstim and...